Compare CWD & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWD | NXL |
|---|---|---|
| Founded | 2009 | 2010 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Real Estate | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 8.3M |
| IPO Year | 2022 | N/A |
| Metric | CWD | NXL |
|---|---|---|
| Price | $1.15 | $0.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 36.4K | ★ 200.4K |
| Earning Date | 03-25-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $51,119,000.00 | N/A |
| Revenue This Year | N/A | $38.28 |
| Revenue Next Year | $26.79 | $185.71 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.20 | $0.36 |
| 52 Week High | $46.21 | $2.57 |
| Indicator | CWD | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 39.11 | 33.91 |
| Support Level | $1.11 | $0.37 |
| Resistance Level | $1.55 | $0.62 |
| Average True Range (ATR) | 0.11 | 0.03 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 12.69 | 21.73 |
CaliberCos Inc is an asset management firm whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. The majority of revenue is derived from the fund management fees segment.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.